Testosterone Cypionate Acne: Severity Grading, Causes, and Management

Testosterone cypionate raises circulating androgen levels above what the body produces on its own. Sebaceous glands in the skin carry androgen receptors, and a portion of testosterone converts locally to dihydrotestosterone (DHT), which binds those receptors more strongly than testosterone itself. This is well-established pharmacology and dermatology, not a novel finding specific to this article. The practical consequence is that some patients on testosterone therapy develop acne that was not present before treatment, ranging from a few blackheads to painful cysts that can scar.

The direct answer: Acne on testosterone cypionate is driven by androgen stimulation of sebaceous glands, it is common enough to be considered an expected possible side effect rather than a rare reaction, and it should be graded and managed like any other acne severity spectrum, with two testosterone-specific levers available in addition to standard acne treatment: adjusting the injection schedule or dose, and reviewing any co-administered aromatase inhibitor. Severe or scarring acne is not something to wait out; it warrants dermatology referral rather than watchful waiting.

Why does testosterone cypionate cause acne?

The pathway is straightforward in outline, even though exact effect sizes for any individual patient are not predictable from a formula:

1. Testosterone cypionate injection raises serum testosterone, with a rise and fall pattern that depends on injection frequency and half-life.
2. Skin, especially on the face, chest, and back, converts some testosterone to DHT locally.
3. DHT activates androgen receptors on sebaceous glands, increasing sebum production.
4. Excess sebum plus shed skin cells can plug the hair follicle, and bacteria that normally live on skin (Cutibacterium acnes) proliferate in that environment, producing inflammatory lesions.

This is the same basic biology behind adolescent acne and other androgen-driven acne (such as some cases in polycystic ovary syndrome), not a mechanism unique to testosterone cypionate. What differs is that TRT delivers an external, sustained androgen source that continues as long as therapy continues, so the acne does not resolve the way a temporary hormonal fluctuation might.

Injection frequency and acne: a plausible but not fully quantified link

Cypionate is a long-acting ester, and once-weekly or less-frequent injections produce a peak shortly after the dose and a trough before the next one. Clinically, some prescribers move patients to more frequent, smaller injections (for example, splitting a weekly dose into two) on the reasoning that smaller peaks may produce less sebum surge. This is a reasonable pharmacokinetic rationale and is used in practice, but the specific size of any acne improvement from this change was not confirmed against a verifiable primary source for this article and should be treated as plausible, not proven. Discuss timing changes with the prescribing clinician rather than adjusting the schedule independently.

Aromatase inhibitors and estradiol

Testosterone converts partly to estradiol in the body. Some evidence suggests estradiol can have a suppressive effect on sebum production, so a patient whose estradiol is pushed very low by an aromatase inhibitor (such as anastrozole, sometimes co-prescribed with TRT) may notice acne worsening. If a patient on TRT is also taking an aromatase inhibitor and develops new or worsening acne, checking estradiol and reviewing whether the aromatase inhibitor dose is higher than needed is a reasonable and low-risk step to raise with the prescriber. This connection is biologically plausible and commonly discussed in endocrinology, but a specific numeric estradiol threshold below which acne reliably worsens was not verifiable from the source material and should not be quoted as an exact cutoff without checking current endocrine society guidance directly.

A five-grade severity framework

No single published rubric exists that was designed and validated specifically for androgen-induced acne in patients on testosterone therapy. What follows adapts general acne severity concepts (comedone count, inflammatory lesion count, presence of nodules or cysts) that are widely used in dermatology, including in FDA guidance for acne drug development, into a framework oriented around what a testosterone patient and prescriber need to decide next. This is a clinical organizing tool, not a validated instrument, and it should not substitute for an in-person exam by a clinician or dermatologist.

Grade 0 to 1 (clear to almost clear). No lesions, or only a few non-inflammatory blackheads/whiteheads. No prescription treatment is generally needed. A non-comedogenic sunscreen and a gentle cleanser (salicylic acid or benzoyl peroxide based) are reasonable, and reassessment at the next scheduled TRT visit is appropriate.

Grade 2 (mild). More than a handful of comedones, or a modest number of inflammatory papules/pustules, without nodules or cysts. Testosterone-related acne at this stage often appears on the back and shoulders as well as the face. Standard first-line topical therapy (benzoyl peroxide, a topical retinoid such as tretinoin) is appropriate, alongside a conversation with the prescriber about whether the injection schedule can be adjusted. Reassessment in about six weeks is a reasonable interval to judge response.

Grade 3 (moderate). Numerous inflammatory lesions or small nodules without frank cysts, often with early scarring changes (post-inflammatory marks). This is generally where oral therapy, most often a tetracycline-class antibiotic paired with topical treatment, gets considered rather than waiting for topicals alone to fail, consistent with general acne treatment guidelines. Checking DHT, free testosterone, and SHBG can help identify whether the current dose is producing an unusually high androgen effect at the tissue level, and a modest testosterone dose reduction may be discussed with the prescriber alongside topical and oral therapy. If there is no meaningful improvement after roughly two months of combined therapy, referral to dermatology is reasonable.

Grade 4 (severe, nodulocystic). Larger nodules or true cysts, meaningful risk of permanent scarring, and often real psychological impact. This grade warrants dermatology referral rather than continued primary-care management alone. Isotretinoin is the standard treatment for nodulocystic acne that has not responded to other measures, and it requires mandatory pregnancy-prevention program enrollment (iPLEDGE) for patients capable of pregnancy, along with baseline and periodic monitoring of liver enzymes, lipids, and other labs, and a labeled warning regarding mood changes that patients and clinicians should discuss before starting. Continuing testosterone therapy during isotretinoin treatment is usually possible and is a shared decision between the TRT prescriber and dermatologist rather than an automatic requirement to stop; that decision should be individualized.

Should you stop or reduce testosterone cypionate for acne?

Usually not as a first step, and not without discussing it with the prescriber. Acne severity should first move management toward standard dermatologic treatment appropriate to the grade. A dose or schedule adjustment is a reasonable secondary lever once acne reaches grade 2 or higher, particularly if labs suggest disproportionately high DHT or free testosterone relative to the therapeutic goal. Full cessation of testosterone therapy is rarely the first response to acne alone, since it also reverses the intended benefits of treatment, and it should be weighed against the severity of the acne, the availability of dermatologic treatment, and the patient's overall treatment goals.

What labs are worth checking

Checking hormone-related labs helps connect a skin change to a modifiable driver rather than guessing. Total testosterone, free testosterone, DHT, SHBG, and estradiol (particularly if an aromatase inhibitor is in use) are the values most often discussed in this context. Reference ranges vary by lab and assay, so any single number should be interpreted by the ordering clinician against that lab's own reference range rather than against a number quoted from an unrelated source.

Lifestyle factors that shift the threshold

Diet and skin care do not cause androgen-driven acne on their own, but they can shift how much acne appears at a given androgen level. High-glycemic-index eating patterns and some protein supplements (notably whey protein, common among patients who are also resistance training) can raise insulin-like growth factor 1 (IGF-1), which has an independent effect on sebaceous gland activity. Patients with grade 2 acne who want to try a non-prescription lever alongside topical treatment sometimes reduce high-glycemic foods or switch protein sources, though this is a supportive measure rather than a substitute for grade-appropriate treatment. Showering soon after exercise and wearing moisture-wicking rather than cotton fabric can reduce friction-related worsening of truncal acne, a simple and low-risk step regardless of severity grade.

When to see a dermatologist rather than wait

Any nodular or cystic acne, any acne that is scarring, and any grade 3 acne that has not improved meaningfully after about two months of combined topical and oral treatment are reasonable triggers for dermatology referral rather than continued self-management. Sudden severe flares with systemic symptoms such as fever, or acne accompanied by significant pain, swelling, or drainage, warrant prompt medical evaluation rather than waiting for a routine follow-up.

Evidence boundary: what is established, what is plausible, what is not confirmed here

Established: Androgens, including exogenous testosterone, stimulate sebaceous gland activity through androgen receptor signaling and local conversion to DHT; this is foundational dermatologic and endocrine physiology, not specific to this brand or ester of testosterone. Standard acne treatments (topical retinoids, benzoyl peroxide, oral tetracyclines, isotretinoin for nodulocystic disease) have general treatment support in dermatology practice independent of the cause of the acne.

Plausible but not confirmed against a verifiable primary source here: Specific numeric claims such as an exact percentage of TRT patients who develop acne, an exact percentage reduction in peak testosterone from splitting injection frequency, or an exact percentage lesion reduction from a particular diet change appeared in earlier drafting material tied to citations that could not be verified as matching their claims. Those precise figures have been removed rather than repeated, because an unverified number stated with confidence is a bigger risk to a reader than an honest "this direction is plausible, exact size unconfirmed."

Not established from the material available: A validated, TRT-specific acne severity grading tool endorsed by a dermatology or endocrine society does not appear to exist; the five-grade framework above is a practical adaptation for organizing decisions, not a validated instrument. A specific DHT or estradiol cutoff that reliably predicts acne severity was not confirmed here and should not be treated as a hard clinical threshold without checking current primary literature or guidelines directly.

Anyone relying on this page for a specific numeric claim (an exact incidence percentage, an exact lab cutoff, an exact expected lesion reduction from a treatment) should verify that number against a current, checkable primary source or current professional guideline before treating it as fact, since the number could not be confirmed against a reliable original source in the material available for this draft.

Decision framework: what changes your next step

This is not a substitute for an exam. It is a way to organize the conversation with a prescriber or dermatologist based on where the acne currently sits and what else is going on.

Exceptions and tradeoffs worth naming out loud:

• Reducing the testosterone dose can help acne but may undercut the reason therapy was started (energy, libido, muscle mass, bone health goals). This tradeoff should be made explicit with the prescriber, not assumed.
• Finasteride to lower DHT is an off-label add-on for this purpose, not an FDA-approved indication for TRT acne, and carries its own risk profile (sexual side effects, and rare reports of persistent symptoms after stopping) that should be discussed before starting.
• Stopping testosterone therapy entirely is rarely required to treat acne, including during an isotretinoin course, but the decision should be individualized between the TRT prescriber and dermatologist rather than defaulted to either continuing or stopping automatically.
• Repeated or prolonged courses of oral antibiotics for acne are generally discouraged because of resistance concerns; a single defined course paired with topical therapy is the more conventional approach.

Frequently asked questions

References

• U.S. Food and Drug Administration. REMS (including iPLEDGE) program information. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm

Note for the editorial and medical reviewer: the prior draft of this article carried numbered citations (PMIDs and a journal DOI) attached to specific numeric claims (peak testosterone reduction percentages, lesion-count reduction percentages, DHT cutoffs, remission rates, and a directly quoted "guideline" sentence). These identifiers could not be verified as matching the claims made next to them, and a targeted primary-source search did not return a confirming result. Those numbers and the quotation have been removed or converted into qualified, non-numeric statements rather than carried forward. Before publication, please verify with the clinical reviewer whether any of these effect sizes can be restored with a correctly matched primary citation; until then they should stay out of the published version.